Chill Pain Away
Capsaicin
Proximity Capital Partners Llc Dba Asutra
Human Otc Drug
NDC 72683-004Chill Pain Away also known as Capsaicin is a human otc drug labeled by 'Proximity Capital Partners Llc Dba Asutra'. National Drug Code (NDC) number for Chill Pain Away is 72683-004. This drug is available in dosage form of Cream. The names of the active, medicinal ingredients in Chill Pain Away drug includes Capsaicin - .025 g/100g . The currest status of Chill Pain Away drug is Active.
Drug Information:
| Drug NDC: | 72683-004 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. |
| Proprietary Name: | Chill Pain Away |
| Also known as the trade name. It is the name of the product chosen by the labeler. |
| Product Type: | Human Otc Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. |
| Non Proprietary Name: | Capsaicin |
| Also known as the generic name, this is usually the active ingredient(s) of the product. |
| Labeler Name: | Proximity Capital Partners Llc Dba Asutra |
| Name of Company corresponding to the labeler code segment of the ProductNDC. |
| Dosage Form: | Cream |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. |
| Substance Name: | CAPSAICIN - .025 g/100g
|
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. |
| Route Details: | TOPICAL
|
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
Marketing Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Marketing Category: | OTC MONOGRAPH NOT FINAL |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
| Marketing Start Date: | 21 Jul, 2020 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. |
| Marketing End Date: | 01 Mar, 2023 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. |
| Application Number: | part348 |
| This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null. |
| Listing Expiration Date: | 26 Dec, 2025 |
| This is the date when the listing record will expire if not updated or certified by the firm. |
OpenFDA Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Manufacturer Name: | Proximity Capital Partners LLC dba Asutra
|
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. |
| Original Packager: | Yes
|
| Whether or not the drug has been repackaged for distribution. |
| UNII: | S07O44R1ZM
|
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. |
Packaging Information:
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|
| 72683-004-01 | 100 g in 1 BOTTLE (72683-004-01) | 21 Jul, 2020 | 01 Mar, 2023 | No |
| 72683-004-02 | 1.9 g in 1 PACKET (72683-004-02) | 21 Jul, 2020 | 01 Mar, 2023 | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. |
Purpose:
Purpose topical analgesic
Product Elements:
Chill pain away capsaicin sodium chloride cetyl palmitate glyceryl stearate se cetostearyl alcohol undecane pentylene glycol cannabidiol alpha-tocopherol acetate tridecane potassium chloride magnesium sulfate, unspecified edetate disodium anhydrous xanthan gum calcium chloride ascorbyl palmitate hydroxyacetophenone almond oil water magnesium chloride dimethyl sulfone shea butter sodium lactate polyglyceryl-2 palmitate xylitylglucoside glyceryl stearate citrate anhydroxylitol xylitol capsaicin capsaicin
Indications and Usage:
Uses temporarily relieves minor aches and pains of muscles and joints associated with: · arthritis ·simple backache · strains · sprains · bruises
Warnings:
Use only as directed. for external use only. keep away from excessive heat or flame
When Using:
When using this product avoid eye contact do not apply to wounds or damaged skin do no bandage tightly
Dosage and Administration:
Directions adults and children over 18 years: apply to affected area. massage into the painful area until thoroughly absorbed. repeat as necessary but no more than 3 to 4 times daily. wash hands with soap and water after applying. children 18 years and younger: consult doctor
Stop Use:
Stop use and ask doctor if: condition worsens symptoms persist for more than 7 days, or clear up and reoccur again within a few days redness is present irritation develops
Package Label Principal Display Panel:
Pdp